Please enable Javascript
Blood Cancers Today Staff Writers
Staff Writers
Articles by Blood Cancers Today Staff Writers
CASTOR Trial Shows Triplet Improves OS Over Doublet in R/R MM
Blood Cancers Today Staff Writers
Myeloma
|
September 21, 2023
The phase III study included patients who received at least one prior line of therapy.
Read More
Study Evaluates Prognostic Value of MRD Assay in Myeloma
Blood Cancers Today Staff Writers
Myeloma
|
September 21, 2023
The researchers sought to assess the utility of MRD outside the context of clinical trials.
Read More
Final Analysis of POLLUX Study Shows OS Benefit with Triplet
Blood Cancers Today Staff Writers
Myeloma
|
September 21, 2023
Daratumumab in combination with lenalidomide and dexamethasone provided greater OS in most subgroups.
Read More
Can Brexu-cel Fill Treatment Gaps for Patients with Relapsed or Refractory MCL?
Blood Cancers Today Staff Writers
Mantle Cell Lymphoma
|
September 9, 2023
Brexucabtagene autoleucel is a promising therapy in relapsed or refractory MCL.
Read More
Does the IPSS-M Have Utility Beyond MDS?
Blood Cancers Today Staff Writers
Myelodysplastic Syndromes
|
September 9, 2023
A research team sought in their study to determine if the IPSS-M could also apply to CMML.
Read More
Pirtobrutinib Is Safe with Antithrombotic Therapy
Blood Cancers Today Staff Writers
Mantle Cell Lymphoma
|
September 8, 2023
Pirtobrutinib can be safely used along with concomitant antithrombotic therapy (CAT) in treating B-cell malignancies.
Read More
Glofitamab Offers High Complete Response Rates for Relapsed or Refractory MCL
Blood Cancers Today Staff Writers
Mantle Cell Lymphoma
|
September 8, 2023
The overall response rate was 83.8% and the CR rate was 73% after the median follow-up of eight months.
Read More
First-Line Induction Regimen Boosts Treatment Response in MCL
Blood Cancers Today Staff Writers
Mantle Cell Lymphoma
|
September 8, 2023
A first-line induction regimen that alternates VR-CAP with R-DHAP can improve treatment response in newly diagnosed MCL.
Read More
Allogeneic HSCT an ‘Attractive’ Treatment Option for MDS Related to Therapy
Blood Cancers Today Staff Writers
Meeting News
|
September 6, 2023
Allogeneic HSCT can yield favorable outcomes in treating patients with therapy-related MDS.
Read More
New Analysis From COMMANDS Trial Reveals More Luspatercept Benefits
Blood Cancers Today Staff Writers
Meeting News
|
September 5, 2023
A presentation by Dr. Rami Komrokji at the Eleventh SOHO Annual Meeting gave additional insights into the COMMANDS trial.
Read More
Luspatercept Shows Effectiveness in ESA-Naïve Patients with Lower-Risk MDS
Blood Cancers Today Staff Writers
Myelodysplastic Syndromes
|
September 5, 2023
Luspatercept is highly effective in treating ESA-naïve patients with LR-MDS.
Read More
Which Treatments Are Linked with Favorable Outcomes in MDS?
Blood Cancers Today Staff Writers
Myelodysplastic Syndromes
|
September 1, 2023
Response rates were high, and OS was improved in patients receiving venetoclax, although not statistically significant.
Read More
Novel Targeted Therapies Shift the Treatment Paradigm in Hodgkin Lymphoma
Blood Cancers Today Staff Writers
Hodgkin Lymphoma
|
August 28, 2023
Single-cell analysis has shed new light on the unique biology of classic Hodgkin lymphoma (HL).
Read More
Belantamab Mafodotin Combo Produced Early, Deep Responses in Newly Diagnosed Disease
Blood Cancers Today Staff Writers
Myeloma
|
June 8, 2023
Researchers are evaluating the combination to establish a recommended phase III dose for the first-line setting.
Read More
Fatal Infection Rates Low with GPRC5D x CD3 Targeting Talquetamab
Blood Cancers Today Staff Writers
Myeloma
|
June 7, 2023
In the trial, patients received talquetamab at 0.4 mg/kg weekly or 0.8 mg/kg every two weeks.
Read More
Liso-Cel Benefited R/R LBCL Regardless of Prior Response to Therapy
Blood Cancers Today Staff Writers
Aggressive B-Cell Lymphoma
|
June 5, 2023
CAR T-cell therapy with lisocabtagene maraleucel resulted in survival benefits for patients with relapsed or refractory.
Read More
Combination Regimen Is Option for Older Adults with Ph- ALL
Blood Cancers Today Staff Writers
Acute Lymphoblastic Leukemia
|
June 5, 2023
Older adult patients with newly diagnosed Ph- ALL may benefit from this combination therapy.
Read More
All-Oral Combo Shows Early Efficacy in R/R MM
Blood Cancers Today Staff Writers
Myeloma
|
June 5, 2023
Patients treated with the higher dose had higher overall response rates.
Read More
Selinexor Could Restore Drug Sensitivity for R/R MM
Blood Cancers Today Staff Writers
Myeloma
|
June 5, 2023
Approximately one-third of the heavily pretreated patients in the small study responded to therapy.
Read More
Cilta-cel LEGEND-2 Data Show Impressive OS in Relapsed or Refractory MM
Blood Cancers Today Staff Writers
Myeloma
|
June 4, 2023
The overall response rate was 87.8% with 73% of patients achieving complete response.
Read More
Load More